Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

ASBPW vs ACB vs SNDL vs IIPR vs CGC

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ASBPW
Aspire Biopharma Holdings, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$160K
5Y Perf.-67.7%
ACB
Aurora Cannabis Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$193M
5Y Perf.-33.1%
SNDL
SNDL Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$372M
5Y Perf.-10.9%
IIPR
Innovative Industrial Properties, Inc.

REIT - Industrial

Real EstateNYSE • US
Market Cap$1.64B
5Y Perf.-20.4%
CGC
Canopy Growth Corporation

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$119M
5Y Perf.-20.7%

ASBPW vs ACB vs SNDL vs IIPR vs CGC — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ASBPW logoASBPW
ACB logoACB
SNDL logoSNDL
IIPR logoIIPR
CGC logoCGC
IndustryBiotechnologyDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericREIT - IndustrialDrug Manufacturers - Specialty & Generic
Market Cap$160K$193M$372M$1.64B$119M
Revenue (TTM)$2K$361M$937M$263M$294M
Net Income (TTM)$-32M$41M$-11M$120M$-327M
Gross Margin45.5%62.7%27.2%60.3%22.8%
Operating Margin-10314.0%13.3%-0.8%46.7%-24.1%
Forward P/E163.5x13.5x
Total Debt$1M$104M$170M$394M$348M
Cash & Equiv.$4K$184M$273M$48M$114M

ASBPW vs ACB vs SNDL vs IIPR vs CGCLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ASBPW
ACB
SNDL
IIPR
CGC
StockFeb 25May 26Return
Aspire Biopharma Ho… (ASBPW)10032.3-67.7%
Aurora Cannabis Inc. (ACB)10066.9-33.1%
SNDL Inc. (SNDL)10089.1-10.9%
Innovative Industri… (IIPR)10079.6-20.4%
Canopy Growth Corpo… (CGC)10079.3-20.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: ASBPW vs ACB vs SNDL vs IIPR vs CGC

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: IIPR leads in 5 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Aurora Cannabis Inc. is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
ASBPW
Aspire Biopharma Holdings, Inc.
The Healthcare Pick

ASBPW plays a supporting role in this comparison — it may shine differently against other peers.

Best for: healthcare exposure
ACB
Aurora Cannabis Inc.
The Growth Play

ACB is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 27.0%, EPS growth 102.2%, 3Y rev CAGR 15.8%
  • 27.0% revenue growth vs ASBPW's -25.4%
  • 5.2% ROA vs ASBPW's -13.2%
Best for: growth exposure
SNDL
SNDL Inc.
The Defensive Pick

SNDL is the clearest fit if your priority is sleep-well-at-night and defensive.

  • Lower volatility, beta 1.17, Low D/E 15.4%, current ratio 4.88x
  • Beta 1.17, current ratio 4.88x
Best for: sleep-well-at-night and defensive
IIPR
Innovative Industrial Properties, Inc.
The Real Estate Income Play

IIPR carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.

  • Dividend streak 9 yrs, beta 0.91, yield 13.3%
  • 439.9% 10Y total return vs ASBPW's -76.9%
  • Better valuation composite
  • 45.6% margin vs ASBPW's -16K%
Best for: income & stability and long-term compounding
CGC
Canopy Growth Corporation
The Healthcare Pick

Among these 5 stocks, CGC doesn't own a clear edge in any measured category.

Best for: healthcare exposure
See the full category breakdown
CategoryWinnerWhy
GrowthACB logoACB27.0% revenue growth vs ASBPW's -25.4%
ValueIIPR logoIIPRBetter valuation composite
Quality / MarginsIIPR logoIIPR45.6% margin vs ASBPW's -16K%
Stability / SafetyIIPR logoIIPRBeta 0.91 vs ASBPW's 3.54
DividendsIIPR logoIIPR13.3% yield; 9-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)IIPR logoIIPR+16.6% vs ASBPW's -56.9%
Efficiency (ROA)ACB logoACB5.2% ROA vs ASBPW's -13.2%

ASBPW vs ACB vs SNDL vs IIPR vs CGC — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

ASBPWAspire Biopharma Holdings, Inc.

Segment breakdown not available.

ACBAurora Cannabis Inc.

Segment breakdown not available.

SNDLSNDL Inc.
FY 2022
Cannabis
100.0%$62M
IIPRInnovative Industrial Properties, Inc.

Segment breakdown not available.

CGCCanopy Growth Corporation
FY 2024
Canadian Cannabis Net Revenue
57.9%$156M
Storz And Bickel
27.3%$73M
International And Other Revenue
14.8%$40M
Other Revenue
0.0%$0

ASBPW vs ACB vs SNDL vs IIPR vs CGC — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLIIPRLAGGINGCGC

Income & Cash Flow (Last 12 Months)

IIPR leads this category, winning 3 of 6 comparable metrics.

SNDL is the larger business by revenue, generating $937M annually — 482943.3x ASBPW's $1,941. IIPR is the more profitable business, keeping 45.6% of every revenue dollar as net income compared to ASBPW's -16351.8%. On growth, CGC holds the edge at +20.9% YoY revenue growth, suggesting stronger near-term business momentum.

MetricASBPW logoASBPWAspire Biopharma …ACB logoACBAurora Cannabis I…SNDL logoSNDLSNDL Inc.IIPR logoIIPRInnovative Indust…CGC logoCGCCanopy Growth Cor…
RevenueTrailing 12 months$1,941$361M$937M$263M$294M
EBITDAEarnings before interest/tax-$28M$71M$49M$197M-$32M
Net IncomeAfter-tax profit-$32M$41M-$11M$120M-$327M
Free Cash FlowCash after capex-$4M-$31M$53M$144M-$86M
Gross MarginGross profit ÷ Revenue+45.5%+62.7%+27.2%+60.3%+22.8%
Operating MarginEBIT ÷ Revenue-10314.0%+13.3%-0.8%+46.7%-24.1%
Net MarginNet income ÷ Revenue-16351.8%+11.2%-1.2%+45.6%-111.0%
FCF MarginFCF ÷ Revenue-1811.5%-8.7%+5.6%+54.7%-29.3%
Rev. Growth (YoY)Latest quarter vs prior year+6.8%-4.4%-3.8%+20.9%
EPS Growth (YoY)Latest quarter vs prior year+46.0%-94.5%+32.8%-1.0%+83.8%
IIPR leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

SNDL leads this category, winning 3 of 5 comparable metrics.

At 14.6x trailing earnings, IIPR trades at a 91% valuation discount to ACB's 163.5x P/E. On an enterprise value basis, ACB's 6.7x EV/EBITDA is more attractive than IIPR's 10.0x.

MetricASBPW logoASBPWAspire Biopharma …ACB logoACBAurora Cannabis I…SNDL logoSNDLSNDL Inc.IIPR logoIIPRInnovative Indust…CGC logoCGCCanopy Growth Cor…
Market CapShares × price$159,937$193M$372M$1.6B$119M
Enterprise ValueMkt cap + debt − cash$1M$135M$297M$2.0B$291M
Trailing P/EPrice ÷ TTM EPS-0.01x163.48x-32.68x14.58x-0.27x
Forward P/EPrice ÷ next-FY EPS est.13.49x
PEG RatioP/E ÷ EPS growth rate3.89x
EV / EBITDAEnterprise value multiple6.69x7.82x10.01x
Price / SalesMarket cap ÷ Revenue0.77x0.54x6.16x0.61x
Price / BookPrice ÷ Book value/share0.43x0.46x0.88x0.33x
Price / FCFMarket cap ÷ FCF8.75x9.37x
SNDL leads this category, winning 3 of 5 comparable metrics.

Profitability & Efficiency

Evenly matched — ACB and IIPR each lead in 3 of 9 comparable metrics.

ACB delivers a 7.2% return on equity — every $100 of shareholder capital generates $7 in annual profit, vs $-43 for CGC. SNDL carries lower financial leverage with a 0.15x debt-to-equity ratio, signaling a more conservative balance sheet compared to CGC's 0.72x. On the Piotroski fundamental quality scale (0–9), ACB scores 7/9 vs ASBPW's 3/9, reflecting strong financial health.

MetricASBPW logoASBPWAspire Biopharma …ACB logoACBAurora Cannabis I…SNDL logoSNDLSNDL Inc.IIPR logoIIPRInnovative Indust…CGC logoCGCCanopy Growth Cor…
ROE (TTM)Return on equity+7.2%-1.0%+6.4%-43.1%
ROA (TTM)Return on assets-13.2%+5.2%-0.8%+5.1%-29.5%
ROICReturn on invested capital+0.7%-0.3%+4.3%-10.2%
ROCEReturn on capital employed+0.7%-0.4%+5.8%-12.4%
Piotroski ScoreFundamental quality 0–937645
Debt / EquityFinancial leverage0.17x0.15x0.21x0.72x
Net DebtTotal debt minus cash$1M-$80M-$102M$346M$235M
Cash & Equiv.Liquid assets$3,633$184M$273M$48M$114M
Total DebtShort + long-term debt$1M$104M$170M$394M$348M
Interest CoverageEBIT ÷ Interest expense-10.51x6.27x-1.16x6.67x-7.79x
Evenly matched — ACB and IIPR each lead in 3 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

IIPR leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in IIPR five years ago would be worth $5,308 today (with dividends reinvested), compared to $46 for CGC. Over the past 12 months, IIPR leads with a +16.6% total return vs ASBPW's -56.9%. The 3-year compound annual growth rate (CAGR) favors IIPR at 4.8% vs CGC's -56.2% — a key indicator of consistent wealth creation.

MetricASBPW logoASBPWAspire Biopharma …ACB logoACBAurora Cannabis I…SNDL logoSNDLSNDL Inc.IIPR logoIIPRInnovative Indust…CGC logoCGCCanopy Growth Cor…
YTD ReturnYear-to-date+4.3%-21.4%-17.5%+19.6%-6.7%
1-Year ReturnPast 12 months-56.9%-28.2%+9.5%+16.6%-17.2%
3-Year ReturnCumulative with dividends-76.9%-47.5%-17.1%+15.1%-91.6%
5-Year ReturnCumulative with dividends-76.9%-95.9%-80.4%-46.9%-99.5%
10-Year ReturnCumulative with dividends-76.9%-92.1%-98.3%+439.9%-94.4%
CAGR (3Y)Annualised 3-year return-38.6%-19.3%-6.0%+4.8%-56.2%
IIPR leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

IIPR leads this category, winning 2 of 2 comparable metrics.

IIPR is the less volatile stock with a 0.91 beta — it tends to amplify market swings less than ASBPW's 3.54 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IIPR currently trades 93.3% from its 52-week high vs ASBPW's 21.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricASBPW logoASBPWAspire Biopharma …ACB logoACBAurora Cannabis I…SNDL logoSNDLSNDL Inc.IIPR logoIIPRInnovative Indust…CGC logoCGCCanopy Growth Cor…
Beta (5Y)Sensitivity to S&P 5003.54x1.80x1.17x0.91x1.95x
52-Week HighHighest price in past year$0.09$6.67$2.89$61.40$2.38
52-Week LowLowest price in past year$0.01$3.07$1.15$44.58$0.84
% of 52W HighCurrent price vs 52-week peak+21.6%+51.1%+49.7%+93.3%+46.6%
RSI (14)Momentum oscillator 0–10047.148.350.656.451.1
Avg Volume (50D)Average daily shares traded22K981K2.0M297K10.3M
IIPR leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: ACB as "Hold", SNDL as "Hold", IIPR as "Hold", CGC as "Hold". Consensus price targets imply 1203.6% upside for CGC (target: $14) vs 47.8% for IIPR (target: $85). IIPR is the only dividend payer here at 13.30% yield — a key consideration for income-focused portfolios.

MetricASBPW logoASBPWAspire Biopharma …ACB logoACBAurora Cannabis I…SNDL logoSNDLSNDL Inc.IIPR logoIIPRInnovative Indust…CGC logoCGCCanopy Growth Cor…
Analyst RatingConsensus buy/hold/sellHoldHoldHoldHold
Price TargetConsensus 12-month target$5.92$3.95$84.67$14.47
# AnalystsCovering analysts1461126
Dividend YieldAnnual dividend ÷ price+13.3%
Dividend StreakConsecutive years of raises9
Dividend / ShareAnnual DPS$7.62
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+3.0%+1.2%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

IIPR leads in 3 of 6 categories (Income & Cash Flow, Total Returns). SNDL leads in 1 (Valuation Metrics). 1 tied.

Best OverallInnovative Industrial Prope… (IIPR)Leads 3 of 6 categories
Loading custom metrics...

ASBPW vs ACB vs SNDL vs IIPR vs CGC: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is ASBPW or ACB or SNDL or IIPR or CGC a better buy right now?

For growth investors, Aurora Cannabis Inc.

(ACB) is the stronger pick with 27. 0% revenue growth year-over-year, versus -13. 8% for Innovative Industrial Properties, Inc. (IIPR). Innovative Industrial Properties, Inc. (IIPR) offers the better valuation at 14. 6x trailing P/E (13. 5x forward), making it the more compelling value choice. Analysts rate Aurora Cannabis Inc. (ACB) a "Hold" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — ASBPW or ACB or SNDL or IIPR or CGC?

On trailing P/E, Innovative Industrial Properties, Inc.

(IIPR) is the cheapest at 14. 6x versus Aurora Cannabis Inc. at 163. 5x.

03

Which is the better long-term investment — ASBPW or ACB or SNDL or IIPR or CGC?

Over the past 5 years, Innovative Industrial Properties, Inc.

(IIPR) delivered a total return of -46. 9%, compared to -99. 5% for Canopy Growth Corporation (CGC). Over 10 years, the gap is even starker: IIPR returned +439. 9% versus SNDL's -98. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — ASBPW or ACB or SNDL or IIPR or CGC?

By beta (market sensitivity over 5 years), Innovative Industrial Properties, Inc.

(IIPR) is the lower-risk stock at 0. 91β versus Aspire Biopharma Holdings, Inc. 's 3. 54β — meaning ASBPW is approximately 291% more volatile than IIPR relative to the S&P 500. On balance sheet safety, SNDL Inc. (SNDL) carries a lower debt/equity ratio of 15% versus 72% for Canopy Growth Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — ASBPW or ACB or SNDL or IIPR or CGC?

By revenue growth (latest reported year), Aurora Cannabis Inc.

(ACB) is pulling ahead at 27. 0% versus -13. 8% for Innovative Industrial Properties, Inc. (IIPR). On earnings-per-share growth, the picture is similar: Aurora Cannabis Inc. grew EPS 102. 2% year-over-year, compared to -381. 5% for Aspire Biopharma Holdings, Inc.. Over a 3-year CAGR, ACB leads at 15. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — ASBPW or ACB or SNDL or IIPR or CGC?

Innovative Industrial Properties, Inc.

(IIPR) is the more profitable company, earning 43. 0% net margin versus -16351. 8% for Aspire Biopharma Holdings, Inc. — meaning it keeps 43. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IIPR leads at 46. 7% versus -10314. 0% for ASBPW. At the gross margin level — before operating expenses — IIPR leads at 88. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is ASBPW or ACB or SNDL or IIPR or CGC more undervalued right now?

Analyst consensus price targets imply the most upside for CGC: 1203.

6% to $14. 47.

08

Which pays a better dividend — ASBPW or ACB or SNDL or IIPR or CGC?

In this comparison, IIPR (13.

3% yield) pays a dividend. ASBPW, ACB, SNDL, CGC do not pay a meaningful dividend and should not be held primarily for income.

09

Is ASBPW or ACB or SNDL or IIPR or CGC better for a retirement portfolio?

For long-horizon retirement investors, Innovative Industrial Properties, Inc.

(IIPR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 91), 13. 3% yield, +439. 9% 10Y return). Aspire Biopharma Holdings, Inc. (ASBPW) carries a higher beta of 3. 54 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IIPR: +439. 9%, ASBPW: -76. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between ASBPW and ACB and SNDL and IIPR and CGC?

These companies operate in different sectors (ASBPW (Healthcare) and ACB (Healthcare) and SNDL (Healthcare) and IIPR (Real Estate) and CGC (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ASBPW is a small-cap quality compounder stock; ACB is a small-cap high-growth stock; SNDL is a small-cap quality compounder stock; IIPR is a small-cap deep-value stock; CGC is a small-cap quality compounder stock. IIPR pays a dividend while ASBPW, ACB, SNDL, CGC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

ASBPW

Quality Business

  • Sector: Healthcare
  • Market Cap > $20B
  • Gross Margin > 27%
Run This Screen
Stocks Like

ACB

Steady Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 6%
Run This Screen
Stocks Like

SNDL

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 16%
Run This Screen
Stocks Like

IIPR

Dividend Mega-Cap Quality

  • Sector: Real Estate
  • Market Cap > $100B
  • Net Margin > 27%
  • Dividend Yield > 5.3%
Run This Screen
Stocks Like

CGC

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 10%
  • Gross Margin > 13%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.